QQQ   341.10 (-1.01%)
AAPL   159.22 (-0.29%)
MSFT   299.84 (+1.05%)
FB   294.64 (+0.00%)
GOOGL   2,580.10 (-0.18%)
AMZN   2,792.75 (+0.55%)
TSLA   829.10 (-11.55%)
NVDA   219.44 (-3.64%)
BABA   111.79 (-1.39%)
NIO   21.11 (-6.84%)
AMD   102.60 (-7.33%)
CGC   6.85 (-5.26%)
MU   78.72 (-3.96%)
GE   89.90 (+0.65%)
T   24.12 (-0.54%)
F   19.55 (-1.81%)
DIS   135.42 (+1.36%)
AMC   14.52 (-8.91%)
PFE   53.37 (+0.68%)
ACB   3.79 (-6.65%)
BA   189.75 (-2.33%)
QQQ   341.10 (-1.01%)
AAPL   159.22 (-0.29%)
MSFT   299.84 (+1.05%)
FB   294.64 (+0.00%)
GOOGL   2,580.10 (-0.18%)
AMZN   2,792.75 (+0.55%)
TSLA   829.10 (-11.55%)
NVDA   219.44 (-3.64%)
BABA   111.79 (-1.39%)
NIO   21.11 (-6.84%)
AMD   102.60 (-7.33%)
CGC   6.85 (-5.26%)
MU   78.72 (-3.96%)
GE   89.90 (+0.65%)
T   24.12 (-0.54%)
F   19.55 (-1.81%)
DIS   135.42 (+1.36%)
AMC   14.52 (-8.91%)
PFE   53.37 (+0.68%)
ACB   3.79 (-6.65%)
BA   189.75 (-2.33%)
QQQ   341.10 (-1.01%)
AAPL   159.22 (-0.29%)
MSFT   299.84 (+1.05%)
FB   294.64 (+0.00%)
GOOGL   2,580.10 (-0.18%)
AMZN   2,792.75 (+0.55%)
TSLA   829.10 (-11.55%)
NVDA   219.44 (-3.64%)
BABA   111.79 (-1.39%)
NIO   21.11 (-6.84%)
AMD   102.60 (-7.33%)
CGC   6.85 (-5.26%)
MU   78.72 (-3.96%)
GE   89.90 (+0.65%)
T   24.12 (-0.54%)
F   19.55 (-1.81%)
DIS   135.42 (+1.36%)
AMC   14.52 (-8.91%)
PFE   53.37 (+0.68%)
ACB   3.79 (-6.65%)
BA   189.75 (-2.33%)
QQQ   341.10 (-1.01%)
AAPL   159.22 (-0.29%)
MSFT   299.84 (+1.05%)
FB   294.64 (+0.00%)
GOOGL   2,580.10 (-0.18%)
AMZN   2,792.75 (+0.55%)
TSLA   829.10 (-11.55%)
NVDA   219.44 (-3.64%)
BABA   111.79 (-1.39%)
NIO   21.11 (-6.84%)
AMD   102.60 (-7.33%)
CGC   6.85 (-5.26%)
MU   78.72 (-3.96%)
GE   89.90 (+0.65%)
T   24.12 (-0.54%)
F   19.55 (-1.81%)
DIS   135.42 (+1.36%)
AMC   14.52 (-8.91%)
PFE   53.37 (+0.68%)
ACB   3.79 (-6.65%)
BA   189.75 (-2.33%)
NASDAQ:TPST

Tempest Therapeutics News Headlines

$3.42
-0.34 (-9.04%)
(As of 01/27/2022 12:00 AM ET)
Add
Compare
Today's Range
$3.42
$4.03
50-Day Range
$3.57
$10.81
52-Week Range
$3.16
$41.55
Volume
41,465 shs
Average Volume
27,131 shs
Market Capitalization
$23.63 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.32
Get Tempest Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for TPST and its competitors with MarketBeat's FREE daily newsletter.

Media Mentions By Week

Tempest Therapeutics Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

TPST
News Sentiment

0.00

0.30

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

TPST Articles
This Week

0

1

TPST Articles
Average Week



Tempest Therapeutics (NASDAQ:TPST) News Headlines Today

SourceHeadline
nasdaq.com logoTempest Therapeutics Inc Shares Fall 2.1% Below Previous 52-Week Low - Market Mover
nasdaq.com - January 15 at 1:40 AM
nasdaq.com logoTempest Therapeutics Inc Shares Near 52-Week Low - Market Mover
nasdaq.com - January 12 at 10:29 AM
finance.yahoo.com logoTempest Announces First Patient Dosed with TPST-1495 in Combination with Pembrolizumab
finance.yahoo.com - November 18 at 12:30 PM
finance.yahoo.com logoTempest Presents Data Supporting the Dual Mechanism of TPST-1495 as an Optimal Approach for Targeting the Prostaglandin Pathway in Cancer
finance.yahoo.com - November 12 at 8:54 AM
finance.yahoo.com logoTempest Reports Third Quarter 2021 Financial Results and Provides Corporate Highlights
finance.yahoo.com - November 10 at 8:16 PM
finance.yahoo.com logoTempest to Present at Two Upcoming Investor Conferences in November
finance.yahoo.com - November 9 at 8:39 AM
finance.yahoo.com logoTempest Further Bolsters Patent Portfolio with Issuance of Multiple Patents for TPST-1495
finance.yahoo.com - November 8 at 3:21 PM
finance.yahoo.com logoTempest Further Bolsters Patent Portfolio with Issuance of Multiple Patents for TPST-1495
finance.yahoo.com - November 8 at 9:05 AM
finance.yahoo.com logoTempest Announces Presentation at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
finance.yahoo.com - October 1 at 8:32 AM
finance.yahoo.com logoTempest Announces First Patient Dosed in Randomized Study Evaluating TPST-1120 in First-Line Regimen for Hepatocellular Carcinoma in Clinical Collaboration with Roche
finance.yahoo.com - September 20 at 10:39 AM
finance.yahoo.com logoTempest Enters into Exclusive License Agreement with the University of California for Novel Cancer Target
finance.yahoo.com - September 13 at 6:22 PM
finance.yahoo.com logoTempest to Present at Upcoming Investor Conferences
finance.yahoo.com - September 9 at 5:39 PM
finance.yahoo.com logoTempest Reports Second Quarter 2021 Financial Results and Provides Corporate Highlights
finance.yahoo.com - August 12 at 5:33 PM
finance.yahoo.com logoTempest Announces Appointment of Ronit Simantov, M.D. to its Board of Directors
finance.yahoo.com - August 9 at 9:51 AM
barrons.com logoTempest Therapeutics Inc.
barrons.com - August 8 at 12:28 AM
nasdaq.com logoTempest Therapeutics, Inc. Common Stock (TPST)
nasdaq.com - July 13 at 10:02 PM
nasdaq.com logo3 Health Care Stocks To Watch This Week
nasdaq.com - July 13 at 1:47 AM
msn.com logoWhat's Going On With Tempest Therapeutics Stock?
msn.com - July 12 at 8:47 PM
reuters.com logoTempest Therapeutics Inc
reuters.com - July 9 at 3:09 PM
finance.yahoo.com logoTempest to Participate in William Blair 2021 Biotech Focus Conference
finance.yahoo.com - July 9 at 10:08 AM
realmoney.thestreet.com logoTempest Therapeutics, Inc. (TPST)
realmoney.thestreet.com - July 8 at 6:18 PM
au.finance.yahoo.com logoTempest Therapeutics Inc. (TPST)
au.finance.yahoo.com - July 3 at 6:13 AM
finance.yahoo.com logoTempest Announces Appointment of Christine Pellizzari to its Board of Directors
finance.yahoo.com - July 1 at 8:16 PM
finanznachrichten.de logoTempest Therapeutics: Tempest Closes Merger with Millendo Therapeutics and Completes PIPE Financing
finanznachrichten.de - June 29 at 2:49 PM
finance.yahoo.com logoTempest and Millendo Announce Stockholder Approval of Merger
finance.yahoo.com - June 22 at 6:50 PM
nasdaq.com logoWill Millendo Therapeutics (NASDAQ:MLND) Spend Its Cash Wisely?
nasdaq.com - May 5 at 3:59 PM
finance.yahoo.com logoIs Millendo Therapeutics (NASDAQ:MLND) In A Good Position To Deliver On Growth Plans?
finance.yahoo.com - May 5 at 3:59 PM
finance.yahoo.com logoMILLENDO ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of MLND and Encourages Investors to Contact the Firm
finance.yahoo.com - May 4 at 12:33 PM
finance.yahoo.com logoMILLENDO INVESTOR ALERT by The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Millendo Therapeutics, Inc. - MLND
finance.yahoo.com - April 8 at 12:39 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Millendo Therapeutics, Inc. Merger
finance.yahoo.com - April 5 at 2:26 PM
markets.businessinsider.com logoSHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Millendo Therapeutics, Inc. - MLND
markets.businessinsider.com - April 3 at 12:25 AM
marketwatch.com logoTempest and Millendo Announce Proposed Merger Agreement - MarketWatch
marketwatch.com - March 31 at 1:15 PM
finance.yahoo.com logoMillendo Therapeutics Stock Is Believed To Be Significantly Overvalued
finance.yahoo.com - March 31 at 1:15 PM
finance.yahoo.com logoMillendo Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Merger of Millendo Therapeutics, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – MLND
finance.yahoo.com - March 31 at 1:15 PM
finance.yahoo.com logoMillendo To Merge With Tempest Therapeutics; Shares Tank
finance.yahoo.com - March 30 at 12:12 PM
markets.businessinsider.com logoMid-Afternoon Market Update: Dow Rises 50 Points; Orphazyme Shares Plunge
markets.businessinsider.com - March 29 at 3:42 PM
markets.businessinsider.com logoMid-Morning Market Update: Markets Mostly Lower; Cal-Maine Foods Reports Mixed Q3 Results
markets.businessinsider.com - March 29 at 10:22 AM
nasdaq.com logoMillendo To Merge With Tempest Therapeutics In An All-Stock Transaction
nasdaq.com - March 29 at 10:22 AM
finance.yahoo.com logoTempest and Millendo Announce Proposed Merger Agreement
finance.yahoo.com - March 29 at 10:22 AM
finance.yahoo.com logoMillendo Therapeutics Provides Pipeline and Business Update
finance.yahoo.com - January 5 at 1:20 PM
in.finance.yahoo.com logoMillendo Therapeutics, Inc. (3OS1.F)
in.finance.yahoo.com - December 19 at 11:54 PM
finance.yahoo.com logoIs MLND A Good Stock To Buy Now?
finance.yahoo.com - December 10 at 4:48 PM
seekingalpha.com logoMillendo Therapeutics EPS beats by $0.12
seekingalpha.com - November 9 at 11:38 AM
finance.yahoo.com logoMillendo Therapeutics Reports Third Quarter 2020 Operating and Financial Results
finance.yahoo.com - November 9 at 11:37 AM
finance.yahoo.com logoMillendo Therapeutics (NASDAQ:MLND) Will Have To Spend Its Cash Wisely
finance.yahoo.com - October 26 at 2:18 PM
businesswire.com logoMillendo Therapeutics Announces Initiation of First-in-Human Clinical Trial of MLE-301, a Selective NK3R Antagonist | Business Wire
businesswire.com - September 25 at 11:19 AM
seekingalpha.com logoMillendo launches early-stage study of lead drug
seekingalpha.com - September 24 at 12:34 PM
seekingalpha.com logoMillendo Therapeutics commences in-human clinical trial for MLE-301
seekingalpha.com - September 24 at 12:34 PM
seekingalpha.com logoMillendo Therapeutics EPS misses by $0.01
seekingalpha.com - August 10 at 12:47 PM
finance.yahoo.com logoMillendo Therapeutics Reports Second Quarter 2020 Operating and Financial Results
finance.yahoo.com - August 10 at 12:47 PM
Get Tempest Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for TPST and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 1/27/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.